First Trust Advisors’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $33.6M | Sell |
640,635
-42,215
| -6% | -$2.23M | 0.02% | 775 |
|
|
2026
Q1 | $37.7M | Sell |
682,850
-63,845
| -9% | -$3.46M | 0.03% | 687 |
|
|
2025
Q4 | $36.6M | Sell |
746,695
-178,136
| -19% | -$8.31M | 0.03% | 700 |
|
|
2025
Q3 | $39.9M | Sell |
924,831
-79,968
| -8% | -$3.12M | 0.03% | 664 |
|
|
2025
Q2 | $38.6M | Sell |
1,004,799
-71,321
| -7% | -$2.73M | 0.03% | 675 |
|
|
2025
Q1 | $41.7M | Sell |
1,076,120
-181,132
| -14% | -$6.63M | 0.04% | 615 |
|
|
2024
Q4 | $42.5M | Buy |
1,257,252
+98,739
| +9% | +$3.55M | 0.04% | 600 |
|
|
2024
Q3 | $47.4M | Buy |
1,158,513
+26,167
| +2% | +$1.07M | 0.05% | 519 |
|
|
2024
Q2 | $43.6M | Buy |
1,132,346
+923,613
| +442% | +$38.9M | 0.04% | 546 |
|
|
2024
Q1 | $8.95M | Buy |
+208,733
| New | +$8.61M | 0.01% | 1054 |
|
|
2022
Q3 | – | Sell |
-1,133,741
| Closed | -$61.7M | – | 2533 |
|
|
2022
Q2 | $61.7M | Sell |
1,133,741
-10,831
| -0.9% | -$598K | 0.08% | 398 |
|
|
2022
Q1 | $62.3M | Buy |
1,144,572
+15,628
| +1% | +$849K | 0.06% | 445 |
|
|
2021
Q4 | $62.2M | Sell |
1,128,944
-87,569
| -7% | -$4.56M | 0.06% | 445 |
|
|
2021
Q3 | $58.1M | Buy |
1,216,513
+33,895
| +3% | +$1.7M | 0.06% | 424 |
|
|
2021
Q2 | $58.9M | Sell |
1,182,618
-85,416
| -7% | -$4.1M | 0.06% | 426 |
|
|
2021
Q1 | $56.6M | Buy |
1,268,034
+79,846
| +7% | +$3.62M | 0.07% | 414 |
|
|
2020
Q4 | $54.7M | Buy |
1,188,188
+88,865
| +8% | +$4.08M | 0.07% | 390 |
|
|
2020
Q3 | $51.7M | Buy |
1,099,323
+191,983
| +21% | +$9.62M | 0.08% | 353 |
|
|
2020
Q2 | $46.3M | Buy |
907,340
+54,874
| +6% | +$2.82M | 0.08% | 354 |
|
|
2020
Q1 | $40.4M | Buy |
852,466
+25,228
| +3% | +$1.35M | 0.09% | 363 |
|
|
2019
Q4 | $48.6M | Buy |
827,238
+51,558
| +7% | +$2.87M | 0.08% | 377 |
|
|
2019
Q3 | $41.4M | Buy |
775,680
+109,237
| +16% | +$5.62M | 0.08% | 379 |
|
|
2019
Q2 | $33.3M | Buy |
666,443
+94,752
| +17% | +$4.75M | 0.06% | 418 |
|
|
2019
Q1 | $29.9M | Buy |
571,691
+72,742
| +15% | +$3.63M | 0.06% | 422 |
|
|
2018
Q4 | $23.8M | Buy |
498,949
+26,044
| +6% | +$1.28M | 0.06% | 444 |
|
|
2018
Q3 | $23.7M | Buy |
472,905
+44,719
| +10% | +$2.27M | 0.04% | 548 |
|
|
2018
Q2 | $21.6M | Sell |
428,186
-16,583
| -4% | -$835K | 0.04% | 535 |
|
|
2018
Q1 | $21.7M | Sell |
444,769
-50,846
| -10% | -$2.37M | 0.05% | 512 |
|
|
2017
Q4 | $22M | Buy |
495,615
+102,550
| +26% | +$4.74M | 0.05% | 515 |
|
|
2017
Q3 | $19.9M | Buy |
393,065
+31,039
| +9% | +$1.57M | 0.05% | 523 |
|
|
2017
Q2 | $19.5M | Buy |
362,026
+11,392
| +3% | +$607K | 0.05% | 511 |
|
|
2017
Q1 | $18.5M | Buy |
350,634
+27,154
| +8% | +$1.38M | 0.05% | 535 |
|
|
2016
Q4 | $15.6M | Buy |
323,480
+61,487
| +23% | +$3.04M | 0.05% | 561 |
|
|
2016
Q3 | $14.1M | Buy |
261,993
+39,481
| +18% | +$2.16M | 0.04% | 576 |
|
|
2016
Q2 | $12.1M | Buy |
222,512
+36,484
| +20% | +$1.92M | 0.04% | 621 |
|
|
2016
Q1 | $9.43M | Buy |
186,028
+39,166
| +27% | +$1.95M | 0.03% | 682 |
|
|
2015
Q4 | $7.41M | Buy |
146,862
+18,526
| +14% | +$944K | 0.02% | 800 |
|
|
2015
Q3 | $6.17M | Sell |
128,336
-8,029
| -6% | -$418K | 0.02% | 872 |
|
|
2015
Q2 | $7.1M | Buy |
136,365
+24,634
| +22% | +$1.39M | 0.02% | 919 |
|
|
2015
Q1 | $6.45M | Sell |
111,731
-3,877
| -3% | -$222K | 0.02% | 940 |
|
|
2014
Q4 | $6.18M | Buy |
115,608
+24,256
| +27% | +$1.36M | 0.02% | 935 |
|
|
2014
Q3 | $5.25M | Buy |
91,352
+17,675
| +24% | +$1.08M | 0.02% | 996 |
|
|
2014
Q2 | $4.92M | Sell |
73,677
-6,721
| -8% | -$455K | 0.02% | 984 |
|
|
2014
Q1 | $5.37M | Sell |
80,398
-661
| -0.8% | -$44.7K | 0.02% | 941 |
|
|
2013
Q4 | $5.41M | Buy |
81,059
+2,654
| +3% | +$172K | 0.03% | 917 |
|
|
2013
Q3 | $4.92M | Buy |
78,405
+5,080
| +7% | +$327K | 0.03% | 885 |
|
|
2013
Q2 | $4.58M | Buy |
+73,325
| New | +$4.65M | 0.03% | 813 |
|
Other funds holding GSK
JEST
First Trust Advisors's GSK Position: Q2 2026 in Review
First Trust Advisors reduced its GSK (GSK) stake by 6.2% in Q2 2026, selling an estimated $2.23M and leaving 640,635 shares worth $33.6M. The position accounts for 0.02% of the portfolio, ranked #775.
First Trust Advisors first reported a position in GSK in Q2 2013 and has held it in 47 quarters since. The position peaked at $62.3M in Q1 2022. 1,040 funds tracked by Wall St. Rank hold GSK as of Q2 2026.
- First Trust Advisors held 640,635 shares of GSK worth $33.6M as of Q2 2026.
- First Trust Advisors sold 42,215 GSK shares in Q2 2026, an estimated $2.23M.
- GSK made up 0.02% of First Trust Advisors's portfolio in Q2 2026, its #775 holding.
- First Trust Advisors first reported a position in GSK in Q2 2013 and has held it in 47 quarters since.
- First Trust Advisors's GSK position peaked at $62.3M in Q1 2022.
- 1,040 funds tracked by Wall St. Rank held GSK as of Q2 2026.
Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.